Part 10/11:
Trump’s announced tariffs on Chinese pharmaceutical imports are expected to increase healthcare costs in America, primarily through higher prices for active pharmaceutical ingredients (APIs). China supplies a significant portion of the US's generic drug ingredients; tariffs could tighten supply and raise costs for medicines like antibiotics and cancer treatments.
The American Hospital Association cautioned that such tariffs might reduce the availability of critical medicines. Meanwhile, Chinese pharmaceutical companies have been expanding their export markets to Europe and developing nations, diversifying their reach beyond the US. This global diversification complicates US efforts to isolate China’s biotech industry economically.